MiNK Therapeutics, Inc.
INKT
$14.57
-$0.33-2.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 74.15% | -0.74% | -63.06% | -35.25% | -40.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.11% | -33.87% | -20.60% | -63.92% | -54.26% |
| Operating Income | -27.11% | 33.87% | 20.60% | 63.92% | 54.26% |
| Income Before Tax | -56.85% | 27.45% | 54.88% | 64.69% | 56.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.85% | 27.45% | 54.88% | 64.69% | 56.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.85% | 27.45% | 54.88% | 64.69% | 56.40% |
| EBIT | -27.11% | 33.87% | 20.60% | 63.92% | 54.26% |
| EBITDA | -27.41% | 34.27% | 21.79% | 64.76% | 54.60% |
| EPS Basic | -46.30% | 36.60% | 60.59% | 69.19% | 59.61% |
| Normalized Basic EPS | -32.95% | 40.47% | 34.35% | 69.19% | 59.37% |
| EPS Diluted | -46.30% | 36.60% | 21.07% | 69.19% | 59.61% |
| Normalized Diluted EPS | -32.95% | 40.47% | 34.35% | 69.19% | 59.37% |
| Average Basic Shares Outstanding | 7.21% | 14.45% | 14.50% | 14.60% | 7.94% |
| Average Diluted Shares Outstanding | 7.21% | 14.45% | 14.50% | 14.60% | 7.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |